Journal Article

Prolonged Suppression of Human Immunodeficiency Virus Type 1 RNA during Dual Nucleoside Reverse-Transcriptase-Inhibitor Therapy in Clinical Practice

Craig J. Hoesley, Michael S. Saag, Ashlee Chatham and J. Michael Kilby

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 31, issue 4, pages 1095-1097
Published in print October 2000 | ISSN: 1058-4838
Published online October 2000 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/318143
Prolonged Suppression of Human Immunodeficiency Virus Type 1 RNA during Dual Nucleoside Reverse-Transcriptase-Inhibitor Therapy in Clinical Practice

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Because there is limited information about suppression of virus loads (determined by current “ultrasensitive” assays) in patients receiving nucleoside reverse-transcriptase inhibitors (NRTIs) alone, we reviewed our experience in clinical practice with patients who had virus loads of <25 copies/ml after >1 year of treatment with dual NRTIs.

Journal Article.  1701 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.